Methamphetamine increases basal ganglia iron to levels observed in aging

NeuroReport

Volumn 18, Issue 16, 2007, Pages 1741-1745

  Melega, William P ^a,b   Laćan, Goran ^a   Harvey, Dennis C ^a   Way, Baldwin M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Ferritin; Globus pallidus; Neurotoxicity; Oxidative stress; Parkinson's disease; Substantia nigra

Indexed keywords

FERRITIN; IRON; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN REGION; CONTROLLED STUDY; DEGENERATIVE DISEASE; GLOBUS PALLIDUS; IMMUNOREACTIVITY; MALE; MONKEY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

AGING; ANIMALS; BASAL GANGLIA; BASAL GANGLIA DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DOPAMINE; FERRITINS; GLOBUS PALLIDUS; IRON; IRON METABOLISM DISORDERS; MALE; METHAMPHETAMINE; OXIDATIVE STRESS; SPECIES SPECIFICITY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 35148837159     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e3282f0d4f4     Document Type: Article

References (25)

1. Beard JL, Connor JD, Jones BC. Brain iron: location and function. Prog Food Nutr Sci 1993; 17:183-221.
2. Hill J, Switzer R. The regional distribution and cellular localization of iron in the rat brain. Neurocsi 1984; 11:595-603.
3. Koeppen A. The history of iron in the brain. J Neurol Sci 1995; 134(Suppl):1-9.
4. Hirsch EC, Faucheux BA. Iron metabolism and Parkinson's Disease. Movement Disord 1998; 13(Supp 1):39-45.
5. Dawson R Jr, Beal MF, Bondy SC, Di Monte DA, Isom GE. Excitotoxins, aging, and environmental neurotoxins: implications for understanding human neurodegenerative diseases. Toxicol Appl Pharmacol 1995; 134:1-17.
6. Mochizuki H, Imai H, Endo K, Yokomizo K, Murata Y, Hattori N, et al. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett 1994; 168:251-253.
7. Sengstock GJ, Olanow CW, Menzies RA, Dunn AJ, Arendash GW. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 1993; 35:67-82.
8. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994; 63:793-806.
9. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003; 53(Suppl 3):S26-S36; discussion S36-S38.
10. Harvey DC, Lacan G, Tanious SP, Melega WP. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 2000; 871:259-270.
11. Goto K, Mochizuki H, Imai H, Akiyama H, Mizuno Y. An immunohistochemical study of ferritin in 1-methly-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Brain Res 1996; 724:125-128.
12. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863-873.
13. Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999; 19:3440-3447.
14. Ono S, Zhang ZD, Marton LS, Yamini B, Windmeyer E, Johns L, et al. Heme oxygenase-1 and ferritin are increased in cerebral arteries after subarachnoid hemorrhage in monkeys. J Cereb Blood Flow Metab 2000; 20:1066-1076.
15. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 1994; 660:8-18.
16. Riederer P, Dirr A, Goetz M, Sofic E, Jellinger K, Youdim M. Distribution of iron in different brain regions and subcellular compartments in Parkinson's Disease. Ann Neurol 1992; 32:S101-S104.
17. Galazka-Friedman J, Friedman A. Controversies about iron in parkinsonian and control substantia nigra. Acta Neurobiol Exp 1997; 57:217-225.
18. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 1991; 56:1441-1444.
19. Jellinger KA, Kienzl E, Rumpelmaier G, Paulus W, Riederer P, Stachelberger H, et al. Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol 1993; 60:267-272.
20. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 2004; 101:9843-9848.
21. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59:1609-1623.
22. Reiderer P, Sofic E, Rausch W, Schmidt B, Reynolds G, Jellinger K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J Neurochem 1989; 52:515-520.
23. Dexter D, Jenner P, Schapira A, Marsden C. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol 1992; 32:S94-S100.
24. Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 2001; 76:1766-1773.
25. Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg RJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005; 23:1-25.